SPOTLIGHT ON STAKEHOLDER SUCCESS

Early diagnosis of maternal cytomegalovirus for improved management and reduced risk of fetal transmission and complications

PATIENT	INCREASED DIAGNOSIS	Implementation of the systematic screening program identified 2.6 times more pregnant women with a cytomegalovirus (CMV) infection. This is based on an increase of 16 more CMV positive expectant mothers post-screening implementation (from 10 to 26) over a 2.5-year period.
	IMPROVED WELLNESS	23% reduction (from 50% to 27%) in congenital CMV (cCMV) transmission from diagnosed CMV-positive pregnant mothers to their babies. This includes full mitigation of 11 congenital transmissions attributable to eligible maternal first trimester treatment, as well as comparable transmission rates (50% vs 47%) in CMV-positive pregnant mothers with untreated CMV, either in the first trimester or beyond.
CLINICIAN	IMPROVED SATISFACTION	"Knowing we're doing everything we can to prevent potentially avoidable transmissions of CMV from pregnant mothers to their babies is emotionally rewarding, especially when symptomatic mothers are concerned for their unborn child. Early antiviral therapy offers hope. -Dr. Caly, Obstetrician in Limoges Hospital
HEALTH SYSTEM / ADMINISTRATION	ENHANCED REPUTATION	The successful rollout of our 7-hospital screening program has facilitated interest across 3 other French hospitals, with whom we are consulting for similar initiatives.
PAYOR	MITIGATED HEALTHCARE COSTS	Reduced cCMV progression with mitigation of long- term health problems (i.e., hearing loss, vision loss, intellectual disabilities) can lead to a cost avoidance of €766,444 per affected child. Based on a conservative cCMV infection rate of 0.4% in France, and 2570 births per year at Limoges hospital [10 neonates are likely infected per year], a 23 % reduction in CMV transmission avoids cCMV in 2-3 neonates, translating to an annual cost avoidance of €1.5-2.3 million at CHU Limoges